Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 2Recruiting 2Completed 2Withdrawn 1Terminated 1Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 2Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 1Leukemia 1

Interventions

venetoclax 38Azacitidine 24fludarabine 20Cytarabine 18Cyclophosphamide 16Specimen Handling 14blinatumomab 13Biopsy 12Busulfan 8Dexamethasone 7Melphalan 6Daunorubicin 6Whole-Body Irradiation 5Vincristine 5Thiotepa 5Methotrexate 5Decitabine 5gilteritinib 4daratumumab 4Tacrolimus 4Stem Cell Transplantation 4Magnetic Resonance Spectroscopy 4Imatinib Mesylate 4Idarubicin 4Exercise 4Blood Specimen Collection 4zanubrutinib 3selinexor 3ruxolitinib 3revumenib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Anthracyclines × Other hematologic neoplasm × Clear all
NCT07060001 2026-03-06

Efficacy of Hypomethylating Agents vs. Intensive Chemotherapy in Acute Myeloid Leukemia Using 5hmC as a Blood-Based Minimal Residual Disease Marker

The Methodist Hospital Research Institute

Phase 2 Not yet recruiting
112 enrolled
Other hematologic neoplasm

Leukemia, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡